Werewolf Therapeutics, Inc. (HOWL)
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
|IPO Date||Apr 30, 2021|
|CEO||Dr. Daniel J. Hicklin Ph.D.|
200 Talcott Avenue, 2nd Floor
Watertown, Massachusetts 02472
|Fiscal Year||January - December|
|Dr. Daniel J. Hicklin Ph.D.||Founder, Chief Executive Officer, President, Secretary and Director|
|Timothy W. Trost CPA||Chief Financial Officer, Treasurer and Assistant Secretary|
|Dr. Chulani Karunatilake Ph.D.||Chief Technology Officer|
|Dr. Reid Leonard Ph.D.||Chief Operating Officer|
|Dr. Cynthia Seidel-Dugan Ph.D.||Chief Scientific Officer|
|Dr. Randi Isaacs M.D.||Chief Medical Officer|
|Ellen A. Lubman M.B.A.||Chief Business Officer|
Latest SEC Filings
|Nov 14, 2023||8-K||Current Report|
|Nov 14, 2023||10-Q||Quarterly Report|
|Nov 3, 2023||8-K||Current Report|
|Sep 18, 2023||8-K||Current Report|
|Aug 10, 2023||8-K||Current Report|
|Aug 10, 2023||10-Q||Quarterly Report|
|Jun 27, 2023||8-K||Current Report|
|May 11, 2023||10-Q||Quarterly Report|
|May 11, 2023||8-K||Current Report|
|Apr 28, 2023||ARS||Filing|